Imagine experiencing burning, tingling, and numbness in your legs day in and day out, getting worse over time — and your doctors can’t find a reason for it.
That’s the situation for millions of people who suffer from idiopathic sensory polyneuropathy. The term “idiopathic” means that no cause can be identified; “sensory” refers to the type of nerve, in this case those carrying nerve signals such as pain or temperature; “poly” means “many” and “neuropathy” means nerve disease. So, this is a condition of unknown cause that damages multiple nerves; the most affected nerves tend to be those that provide sensation to the legs and feet.
Sometimes other terms are used, including cryptogenic neuropathy or chronic polyneuropathy of undetermined cause. For some people, neuropathy is due to diabetes, alcohol abuse, medications, or other conditions. But in nearly half of all cases, sensory polyneuropathy is idiopathic.
No cause, no cure
Regardless of which name is used, the condition is frustrating, annoying, and sometimes debilitating. And without an identifiable and reversible cause, there is no cure. While a number of medications are commonly prescribed, it’s not clear which is most effective or safest. So, doctors generally recommend a period of trial and error. One medication after another is prescribed, until one is found that is effective and doesn’t cause intolerable side effects.
Unfortunately, it can take many months or even longer to find a treatment that works. Doctors have little guidance to know which ones to start with. That’s why research comparing treatment options is so important — and yet, precious little comparative research on treatments for idiopathic sensory polyneuropathy has been published.
Researchers compare four treatments for neuropathy
Researchers publishing in JAMA Neurology describe the results of a unique trial in which 402 people with idiopathic sensory polyneuropathy were randomly assigned to one of four medications: duloxetine, mexiletine, nortriptyline, or pregabalin. After 12 weeks, each person rated their neuropathy symptoms on a scale from 1 to 10, noted any side effects, and reported whether they had quit taking the medication due to side effects, cost, or some other reason.
Though the trial is important and much needed, the results were disappointing.
- No medication was a clear winner or highly effective. For this study, a key measure was whether a medication reduced discomfort by 50%. The most effective treatment was nortriptyline. Of the study subjects taking this medication, 25% reported their discomfort improved by at least 50%. The least effective treatment was pregabalin: only 15% of study subjects reported that much improvement.
- Side effects were common with all of the treatments. Nortriptyline had the highest rate of side effects, at 56%. Mexiletine had the fewest at 39%. Fortunately, none of the side effects were considered serious.
- People frequently quit taking the assigned medication. Duloxetine had the fewest discontinuations (37%). The highest quit rate was for mexiletine (58%). Reasons given for stopping included side effects and cost.
The study wasn’t perfect
This trial had a number of important limitations:
- The trial lasted only 12 weeks. For a condition that is typically lifelong, longer-term results would be more helpful.
- The four medications compared in this trial were chosen because they work in different ways. But other commonly prescribed drugs were not included. For example, this trial tells us nothing about how well gabapentin, amitriptyline, or carbamazepine would have performed.
- Study subjects could be treated with a medication they had taken before the trial, even if it hadn’t worked for them.
- The quit rate included factors unrelated to how safe or effective the medication was. Medication cost was particularly important in this regard.
- Most of the study subjects (85%) were white. Results could have been different if a more diverse study population had been enrolled.
The bottom line
Direct comparisons of treatments for idiopathic sensory polyneuropathy — which many simply call neuropathy — are sorely needed, so this trial is important. Yet, the biggest take-home message of this research is that many current treatments aren’t very good.
Overall, nortriptyline and duloxetine appeared to outperform the other drugs in this trial, so they would be good choices to start with rather than pregabalin and mexiletine. But when the best treatments work well for only a quarter or less of patients, and nearly half quit treatment in the first 12 weeks, it’s clear that better, safer, and less expensive treatments are needed.
Perhaps we already have better treatments that weren’t part of this trial. We’ll need additional comparative research to know for sure.
Follow me on Twitter @RobShmerling
As a service to our readers, Harvard Health Publishing provides access to our library of archived content.
Please note the date of last review or update on all articles. No content on this site, regardless of date,
should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Commenting has been closed for this post.